VANCOUVER, BC / ACCESSWIRE / September 27, 2016 / Phillip Thomas, President of Arrowstar Resources Ltd. (“Arrowstar” or the “Company”) (TSX.V: AWS), is pleased to announce that the Company has received the laboratory results on 60 pulp samples taken from reverse circulation drill cuttings in the Tin Cup (“Secret Pass”) concessions, that is located 26 miles north of Kingman, Arizona.

From 1984-1991 a total of 126 drill holes totaling 14,036m were completed on the Tin Cup property. Pulp samples from five holes were selected and re-assayed for quality control purposes to determine the reliability of the historic drill data and determine if it would be necessary to twin and re-assay the previous drill holes.

The 63 re-assayed pulp samples had a correlation to the original results of more than 90% after outliers were removed. As a result of these positive results it was determined that the drill data from the previous 125 drill holes is reliable within the sampling error range and as such, twinning the drill holes and re-assaying will serve no useful purpose.

The Board has decided to commence preparation for Phase 2 Drilling which will be a 10 hole drill program that has already been permitted for.

Phil Thomas, Arrowstar’s President and Chief Geologist states,”We are very pleased to have completed the QA/QC stage of the due diligence process. We anticipate two phases of drilling programs that we expect will allow the Company to define a current resource on the property, allow us to complete a feasibility study and mining implementation plans. The project is well advanced to potentially be fast tracked to production when drilling, resource estimation and project economics is completed.”

Pulp sampling highlights:

The original sample analyses produced by Union, CMS and MSRD laboratories in 1985-1988 were correlated 63% without any normalization for sampling error, and were analyzed using ICP by fire assay fusion. After outliers were removed, the correlation was more than 90%.
Thirty three other elements were assayed by aqua regis then ICP with highs of Manganese, and low values (<120ppm) Arsenic, Copper, Platinum, Palladium, Iron and Silver.
The sampling was done by Bureau Veritas Commodities Canada Ltd (“Bureau Veritas”), Vancouver, using ICP and fire assay, with preparation of the pulp samples to ensure they were homogenous. The holes sampled were TC1, TC3, TC10, TC30, and TC32.
The samples analyzed for Gold were:

Number greater than 11 gms per tonne – 0 10/63
Number greater than 4 gms per tonne – 21/63

To view the graphic, please click here

Four samples were significant outliers to the population in percentage terms, and these were:

Hole

Sample depth – feet

1987 Assay gms/tonne

2016 Assay gms/tonne

TC1

70-75

3.068

7.938

TC3

90-95

0.015

0.044

TC30

495-500

0.311

0.696

TC32

60-65

5.16

>11.00

Quality Control

The sampling of Secret Pass drill core and reverse circulation cuttings was supervised by Bud Hillemeyer CP, who was responsible for all aspects of the original work. Phil Thomas MAIG MAIMVA was responsible for identification and packaging of the pulp samples. The on-site personnel at the project pulled sampled pulps from on-site storage and then security sealed and shipped them to Bureau Veritas Laboratories in Vancouver, British Columbia for analysis. Bureau Veritas’ quality control system complies with the requirements for the International Standards ISO 9001:2008. Analytical accuracy and precision were monitored by the analysis of six reagent blanks, four insertions of standard reference material, and six duplicate samples.

The Company also announces it has terminated the Investor Relations Agreement with Lawrie Koyle. The Company would like to thank Mr. Koyle for his services to the Company and wish him well in his future endeavors.

Qualified Person

Phillip Thomas, BSc Geol, MBusM, MAIG, MCIM MAIMVA, CMV CIM, a Qualified Person as defined under NI 43-101 regulations, has reviewed the technical information that forms the basis for portions of this news release, and has approved the disclosure herein. Mr. Thomas is not independent of the Company as he is an Officer and a shareholder.

On Behalf of the Board of Directors,
Arrowstar Resources Ltd.

“Phillip Thomas”
President

Investor Contact:

604-687-7828
phil@arrowstarresources.com
www.arrowstarresources.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-Looking Statements: This document includes forward-looking statements. Forward-looking statements include, but are not limited to, statements concerning AWS’s planned exploration programs in North America and other statements that are not historical facts. When used in this document, the words such as “could,” “plan,” “estimate,” “expect,” “intend,” “may,” “potential,” “should,” and similar expressions are forward-looking statements. Although AWS believes that its expectations reflected in these forward looking statements are reasonable, such statements involve risks and uncertainties and no assurance can be given that actual results will be consistent with these forward-looking statements. Important factors that could cause actual results to differ from these forward-looking statements are disclosed under the heading “Risk Factors” and elsewhere in the corporation’s periodic filings with Canadian securities regulators.

SOURCE: Arrowstar Resources Ltd.

ReleaseID: 446115

IRVINE, CA / ACCESSWIRE / September 27, 2016 / Khang & Khang LLP (the “Firm”) announces a class action lawsuit was filed against Keryx Biopharmaceuticals Inc. (“Keryx” or the “Company”) (Nasdaq: KERX). Investors who purchased or otherwise acquired shares between February 25, 2016 and August 1, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 3, 2016 lead plaintiff motion deadline.

If you purchased Keryx shares during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that during the Class Period, Keryx made false and misleading statements and/or failed to disclose: that Keryx was experiencing production-related difficulties in converting API to finished drug product; that the issue was resulting in fewer production yields of finished drug product; that the Company exhausted its reserve of finished drug product; and as a result of the above, Keryx’s statements about its business, operations and prospects were false and misleading and/or lacked a reasonable basis at all relevant times. When this information emerged to the public, the stock price of Keryx fell.

If you wish to learn more about this lawsuit, or if you have questions concerning this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in certain jurisdictions.

Contacts

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 446111

IRVINE, CA / ACCESSWIRE / September 27, 2016 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Power Solutions International, Inc. (“Power Solutions” or the “Company”) (NASDAQ: PSIX). Investors who purchased or otherwise acquired shares between May 8, 2015 and August 15, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 21, 2016 lead plaintiff motion deadline.

If you purchased shares of Power Solutions during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

The complaint alleges that through the Class Period, Power Solutions made false and misleading statements and/or failed to disclose that: the Company inappropriately recognized revenue for certain transactions; that the Company lacked adequate internal controls over financial reporting; and that as a result of the above, Power Solutions’ public statements were materially false and misleading at all relevant times. On August 15, 2016, Power Solutions announced that it would delay filing its Form 10-Q for the quarter ending June 30, 2016 because its financial statements were incomplete due to possible problems with certain transactions involving revenue recognition. When this information was released to the public, Power Solutions’ stock price decreased, which caused investors harm.

If you wish to learn more about this lawsuit, or if you have any questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.

Telephone: 949-419-3834

Facsimile: 949-225-4474

joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 446112

IRVINE, CA / ACCESSWIRE / September 27, 2016 / Khang & Khang LLP (the “Firm”) announces the filing of a class action lawsuit against Corrections Corporation of America (“Corrections Corporation” or the “Company”) (NYSE: CXW). Investors who purchased or otherwise acquired shares between February 27, 2012 and August 17, 2016 inclusive (the “Class Period”), are encouraged to contact the Firm prior to the October 24, 2016 lead plaintiff motion deadline.

If you purchased shares of Corrections Corporation during the Class Period, please contact Joon M. Khang, Esquire, of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at joon@khanglaw.com.

There has been no class certification in this case. Until certification occurs, you are not represented by an attorney. You may choose to take no action and remain a passive class member.

According to the complaint, during the Class Period, Corrections Corporation made false and/or misleading statements and/or failed to disclose: that the Company’s facilities lacked adequate safety and security standards and were less efficient at offering correctional services than the Federal Bureau of Prisons’ (“BOP”) facilities; that the Company’s rehabilitative services for inmates were less effective than the BOP’s services; that the U.S. Department of Justice (“DOJ”) was unlikely to renew and/or extend its contracts with Corrections Corporation; and that as a result of the above, Corrections Corporation’s public statements were materially false and misleading at all relevant times. On August 18, 2016, Deputy Attorney General Sally Yates announced that the DOJ decided to stop using private prisons, since they are less safe and less effective than federal government-run prisons. When this news emerged to the public, Corrections Corporation’s stock price decreased, thus causing investors harm.

If you wish to learn more about this lawsuit, or if you have questions regarding this notice or your rights, please contact Joon M. Khang, a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at joon@khanglaw.com.

This press release may constitute Attorney Advertising in some jurisdictions.

Contacts

Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
joon@khanglaw.com

SOURCE: Khang & Khang LLP

ReleaseID: 446109

LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces that a class action lawsuit was filed against Tokai Pharmaceuticals, Inc. (“Tokai” or the “Company”) (NASDAQ: TKAI) concerning possible violations of federal securities laws between June 24, 2015 and July 25, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the September 30, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

According to the Complaint, Tokai made false and misleading statements and/or failed to disclose: that there were significant structural problems with the trial design for its Phase 3 galeterone study, ARMOR3-SV; that ARMOR3-SV was unlikely to succeed in meeting its primary endpoint; the commercialization of galeterone was less likely than investors were led to believe; and as a result of the above, Tokai’s statements about its business, operations, and prospects were false and misleading at all relevant times. When this news emerged to the public, Tokai’s stock price declined, causing investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding the rights of shareholders.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446110

Funding Supports Open Source Data Science Tools Widely Used in Academia and Industry

NEW YORK, NY / ACCESSWIRE / September 27, 2016 / NumFOCUS, a 501(c)(3) nonprofit supporting and promoting open source scientific computing, today is announcing IBM as a Platinum Corporate Sponsor to further research, education and development of data science tools using Python, Julia and R.

Data Science tools fiscally sponsored by NumFOCUS serve as a catalyst for scientific discovery and industry breakthroughs in the management of data. “IBM’s work with NumFOCUS continues the advancement of open source data science tools. Our communities’ contributions have enabled countless companies to build data driven environments. With IBM’s support, we continue to help our community sustain and innovate. This contribution will help fund special projects and outreach to a diverse community that we hope continues to fuel innovation throughout the world,” said Andy Terrel, NumFOCUS board president.

Through the sponsorship, IBM is supporting for the Python community of approximately 30 million users by providing native support for Python within its IBM Analytics portfolio. IBM’s support will help to fund both the needs of NumFOCUS projects, as well as the needs of the community, through continued diversity and educational programs such as PyData conference series. The PyData conference series helps to connect users and developers of the Python data science stack, Julia, Stan and R-based scientific tools, resulting in invaluable opportunities to share knowledge of varied use cases and provide instruction to new users. To advance the industry, 200 diversity scholarships are given out each year to ensure a diverse group is able to attend events and engage in the community.

As one of the global leaders in data analytics and management, IBM has invested in software and technology solutions designed to help enterprises gain powerful insights from data. The company relies on Python, among other data languages, to help create innovative solutions. As a Platinum sponsor of NumFOCUS, IBM will share these insights as it engages with the community through a seat on the NumFOCUS Advisory council, providing advice and input to the organization.

Today’s news furthers IBM’s commitment to advance Spark as the analytics operating system helping to accelerate innovation and drive analytics across businesses. IBM continues to partner with leading data science organizations, including Continuum, Galvanize, H2O, LightBend and RStudio, to promote an integrated and unified data science ecosystem. Additionally, in June, IBM joined the R Consortium to help accelerate data science readiness for the enterprise.

About NumFOCUS:

NumFOCUS is a 501(c)(3) nonprofit that supports and promotes world-class, innovative, open source scientific software. The mission of NumFOCUS is to promote sustainable high-level programming languages, open code development, and reproducible scientific research. We accomplish this mission through our educational programs and events as well as through fiscal sponsorship of open source data science projects. From the LIGO Gravitational Waves Discovery, confirming the observation of gravitational waves emanating from the merger of two black holes; to a real-time automated trading platform, these projects are empowering users to solve some of today’s greatest challenges facing the world.

To learn more about NumFOCUS, visit www.numfocus.org.

Contact:

Savannah Mercado
NumFOCUS Communications
media@numfocus.org

SOURCE: NumFOCUS

ReleaseID: 446095

LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces the filing of a class action lawsuit against American Renal Associates Holdings, Inc. (“ARA” or the “Company”) (NYSE: ARA) concerning possible violations of federal securities laws. Investors who purchased or otherwise acquired shares 1) pursuant and/or traceable to the Initial Public Offering (“IPO”) on or about April 21, 2016; and/or 2) on the open market between April 21, 2016 and August 18, 2016 (the “Class Period”), should contact the Firm in advance of the October 31, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that ARA issued false and misleading statements to investors and/or failed to disclose that: the Company was engaged in a fraudulent scheme to steer patients away from Medicare and Medicaid plans they qualified for, into more expensive Affordable Care Act plans to obtain greater reimbursement for its dialysis services; the scheme was in violation of federal and state laws; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. When this news was disclosed to the public, the stock price of ARA fell, which caused investors harm.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446108

LOS ANGELES, CA / ACCESSWIRE / September 27, 2016 / Lundin Law PC (the “Firm”) announces the filing of a class action lawsuit against LifeVantage Corporation (“LifeVantage” or the “Company”) (NASDAQ: LFVN) concerning possible violations of federal securities laws between November 4, 2015 and September 13, 2016 (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the Firm before the November 14, 2016 lead plaintiff motion deadline.

To participate in this class action lawsuit, click here. You can also call Brian Lundin, Esquire, of Lundin Law PC, at 888-713-1033, or e-mail him at brian@lundinlawpc.com.

No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.

The complaint alleges that during the Class Period, LifeVantage made false and/or misleading statements and/or failed to disclose: that the Company lacked effective internal financial controls; that LifeVantage improperly accounted for sales in certain international markets, along with associated revenue and income tax accruals; and that as a result of the above, the Company’s public statements were materially false and misleading at all relevant times.

On September 13, 2016, the Company announced that it would delay the release of its fourth quarter and fiscal year 2016 financial results. The reason for the delay was for LifeVantage to carry out an internal review of sales into certain international markets and the revenue and income tax associated with those sales. The Company stated that it is unable to estimate the impact of the review to aspects of its financial statements for the fiscal year ended June 30, 2016 or any potential prior periods. When this information was released, shares of LifeVantage decreased in value.

Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.

This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.

Contact:

Lundin Law PC

Brian Lundin, Esq.

Telephone: 888-713-1033

Facsimile: 888-713-1125

brian@lundinlawpc.com
http://lundinlawpc.com/

SOURCE: Lundin Law PC

ReleaseID: 446107